Cats. Dust mites. Mold. Trees.

For people with allergies, even a brief whiff of the airborne allergens these organisms produce can lead to swollen eyes, itchy skin and impaired breathing.

Such allergens can persist indoors for months after the original source is gone, and repeated exposure can exacerbate, and even lead to, asthma.

What if you could just flip a switch and disable them? You can, according to new University of Colorado Boulder research.

"We have found that we can use a passive, generally safe ultraviolet light treatment to quickly inactivate airborne allergens," said study author Tess Eidem, a senior research associate in the Department of Civil, Environmental and Architectural Engineering.

"We believe this could be another tool for helping people fight allergens in their home, schools or other places where allergens accumulate indoors."

The findings were published in August in the journal ACS ES&T Air.

Why you can't kill an allergen

Walk into a room with a cat and, if you sneeze, it's not actually the cat you are reacting to. It's likely airborne flecks of a protein called Fel d1 produced in their saliva. The protein spreads when they lick themselves and ends up in microscopic flakes of dead skin floating in the air, a.k.a. dander. When we inhale these particles, our immune system produces antibodies that bind to the protein's unique 3D structure, kicking off an allergic reaction.

Dogs, mice, dust mites, mold and plants all emit their own unique proteins, with their own unique structure. Unlike bacteria and viruses, these allergens can't be killed because they were never alive.

"After those dust mites are long gone, the allergen is still there," said Eidem. "That's why, if you shake out a rug, you can have a reaction years later."

Standard methods of reducing allergens -- like vacuuming, washing walls, using an air filter and regularly bathing pets -- can work OK but are hard to maintain long-term studies show.

Eidem and co-authors Mark Hernandez, a professor of Civil, Environmental and Architectural Engineering, and Kristin Rugh, a microbiologist in the lab, sought a simpler way.

Instead of eliminating the proteins that cause allergies, they sought to change their structure -- much like unfolding an origami animal -- so the immune system wouldn't recognize them.

"If your immune system is used to a swan and you unfold the protein so it no longer looks like a swan, you won't mount an allergic response," explained Eidem.

UV light, their study suggests, can do that.

Let there be light

Previous research has shown that UV light can kill airborne microorganisms, including the virus that causes COVID-19.

It's already used widely to disinfect equipment in hospitals, airports and elsewhere, but the bandwidth is typically so strong (a wavelength of 254 nanometers) that users must wear protective equipment to prevent damage to skin and eyes.

Eidem used 222-nanometer-wavelength lights, a less-intense alternative considered safe for occupied spaces because it doesn't penetrate deep into cells. (It does not come entirely without risks, including ozone production, she notes, so exposure should be limited.)

The team pumped microscopic aerosolized allergens from mites, pet dander, mold and pollen into an unoccupied and sealed 350-cubic-foot chamber. Then they switched on four lunchbox-sized UV222 lamps on the ceiling and floor.

When they sampled the air at 10-minute intervals and compared it to untreated, allergen-filled air via laboratory tests, they saw significant differences. In the treated samples, immunorecognition was reduced, meaning the antibodies no longer recognized many of the proteins and stuck to them.

After just 30 minutes, airborne allergen levels effectively decreased by about 20% to 25% on average, the study showed.

"Those are pretty rapid reductions when you compare them to months and months of cleaning, ripping up carpet, and bathing your cat," said Eidem.

A portable allergy buster?

UV222 lights are already commercially available, mostly for industrial antimicrobial uses.

But Eidem envisions a day when companies could engineer portable versions for people to switch on when they visit a friend with a pet or clean out a dusty basement.

UV222 systems could also potentially protect workers frequently exposed to allergens, such as those who work around live animals or in cannabis grow houses where, her own research shows, allergic reactions can be deadly.

One-in-three adults and children in the United States have allergies, according to the Centers for Disease Control. Eidem hopes her research, and more to come, can provide them with some relief -- or even save lives.

"Asthma attacks kill about 10 people every day in the United States, and they are often triggered by airborne allergies," she said. "Trying to develop new ways to prevent that exposure is really important."

Read more …Sneezing from cats or dust? Safe UV light may neutralize allergens in minutes

On Sept. 3, 2025, Florida announced its plans to be the first state[1] to eliminate vaccine mandates for its citizens[2], including those for children to attend school.

Current Florida law and the state’s Department of Health[3] require that children who attend day care or public school be immunized for polio, diphtheria, rubeola, rubella, pertussis and other communicable diseases. Dr. Joseph Ladapo, Florida’s surgeon general...

Read more

Researchers at UT Southwestern Medical Center have discovered how a hormone interacts with a receptor on the surface of immune cells to shield cancer cells from the body's natural defenses. The findings, published in Nature Immunology, could lead to new immunotherapy approaches for treating cancer as well as potential treatments for inflammatory disorders and neurologic diseases.

"Myeloid cells are among the first group of immune cells recruited to tumors, but very quickly these tumor-fighting cells turn into tumor-supporting cells. Our study suggests that receptors on these myeloid cells get stimulated by this hormone and end up suppressing the immune system," said Cheng Cheng "Alec" Zhang, Ph.D., Professor of Physiology and a member of the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern. Dr. Zhang co-led the study with first author Xing Yang, Ph.D., a postdoctoral researcher in the Zhang Lab.

Current immunotherapies, such as immune checkpoint inhibitors, are effective for only about 20%-30% of cancer patients, Dr. Zhang said, suggesting that there are multiple ways that cancers evade attack from the immune system.

Several years ago, researchers in the Zhang Lab studying cancer-fighting immune cells called myeloid cells identified an inhibitory receptor called LILRB4. Stimulating this receptor blocked the myeloid cells' ability to attack tumors.

Dr. Zhang, Dr. Yang, and their colleagues then did a genome-wide screen of all proteins that might interact with LILRB4. A promising hit was a hormone called SCG2. Although researchers have suggested that SCG2 plays a role in immune response, its function and receptor were unknown. Laboratory experiments confirmed that SCG2 binds to LILRB4, kicking off a signaling cascade that turned off the cancer-fighting abilities of myeloid cells and inhibited their ability to recruit cancer-fighting T cells to tumors.

In mice genetically altered to express the human form of LILRB4, injected cancer cells that produced SCG2 grew rapidly as tumors. Treating these mice with an antibody that blocks LILRB4 significantly slowed cancer growth, as did artificially ridding the animals' bodies of SCG2.

Together, these experiments suggest that interactions between LILRB4 and SCG2 allow cancer to grow unchecked by myeloid cells, T cells, and potentially other immune cell types. Dr. Zhang suggested that disrupting this interaction could someday offer a new immunotherapy option to treat cancer. Conversely, because this interaction neutralizes myeloid cells' immune activity, delivering extra SCG2 could be a promising treatment for autoimmune or inflammatory disorders spurred by myeloid cells. Dr. Zhang and his colleagues plan to investigate both ideas in future studies.

Other UTSW researchers who contributed to this study include Xuewu Zhang, Ph.D., Professor of Pharmacology and Biophysics; Cheryl Lewis, Ph.D., Associate Professor in the Simmons Cancer Center and of Pathology; Lin Xu, Ph.D., Assistant Professor in the Peter O'Donnell Jr. School of Public Health and of Pediatrics; Jingjing Xie, Ph.D., Instructor of Physiology; Qi Lou, Ph.D., Assistant Instructor of Physiology; Lei Guo, Ph.D., Computational Biologist; and Meng Fang, Ph.D., Chengcheng Zhang, Ph.D., Ankit Gupta, Ph.D., and Lianqi Chen, Ph.D., postdoctoral researchers.

Dr. Alec Zhang holds the Hortense L. and Morton H. Sanger Professorship in Oncology and is a Michael L. Rosenberg Scholar in Medical Research. Dr. Xuewu Zhang and Dr. Xu are members of the Simmons Cancer Center.

This study was funded by grants from the National Cancer Institute (NCI) (R01CA248736, R01CA263079, and Lung Cancer 779 SPORE Development Research Program), the Cancer Prevention and Research Institute of Texas (RP220032, RP15150551, RP190561), The Welch Foundation (AU-0042-20030616, I-1702), Immune-Onc Therapeutics Inc. (Sponsored Research Grant No. 111077), the National Institutes of Health (R35GM130289), and NCI Cancer Center Support Grant (P30CA142543).

The University of Texas has a financial interest in Immune-Onc in the form of equity and licensing. Dr. Alec Zhang holds equity in and had sponsored research agreements with Immune-Onc.

Read more …A hormone that silences the immune system may unlock new cancer treatments

More Articles …